Pharmacokinetics in children

No information is present at this moment.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Renal impaiment in children > 3 months

No information available on dose adjustment in renal impairment.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects

No information is present at this moment.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions

No information available on specific warnings and precautions in children.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

• DERMATOLOGICALS
• ANTIPSORIATICS

ANTIPSORIATICS FOR TOPICAL USE

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

References

1. Nederlandse Vereniging voor Dermatologie en Venereologie (NDVD), Multidisciplinaire evidencebased richtlijn Psoriasis, https://nvdv.nl/richtlijnen-en-onderzoek/richtlijnen/richtlijn-psoriasis, 2017
2. Perez A, et al., Pilot study of topical calcitriol (1,25-dihydroxyvitamin D3) for treating psoriasis in children. , Arch Dermatol., 1995, 131(8), 961-2
3. Saggese G, et al., Topical application of 1,25-dihydroxyvitamin D3 (calcitriol) is an effective and reliable therapy to cure skin lesions in psoriatic children., Eur J Pediatr. , 1993, 152(5), 389-92

Changes

Therapeutic Drug Monitoring

Overdose